Potent and selective fatty acid binding protein 4, adipocyte (FABP4) inhibitor (Ki
values are <2, 250 and 350 nM for FABP4, FABP3 and FABP5 respectively). Decreases fatty acid uptake in adipocytes in vitro
and reduces atherosclerotic lesion area in a mouse model of atherosclerosis. Reduces blood glucose levels and increases insulin sensitivity in a mouse model of obesity. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2.
Furuhashi et al.
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Sulsky et al.
BMS309403 stimulates glucose uptake in myotubes through activation of AMP-activated protein kinase.
Lin et al.
PLoS ONE, 2012;7:e44570